Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused
on driving innovation to transform outcomes for cancer patients,
today announced details of its upcoming presentation of initial
data from the ongoing Phase 1 dose escalation and expansion
clinical trial of ONCR-177 at the upcoming Society for
Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place
November 12–14, 2021 in Washington, D.C. and virtually. ONCR-177,
Oncorus’ lead product candidate built on the company’s oncolytic
Herpes Simplex Virus (HSV) platform, is an intratumorally
administered viral immunotherapy being developed for the treatment
of multiple solid tumor indications.
Poster Presentation
Details:Title: Initial results of a Phase
1 study of intratumoral ONCR-177, an oncolytic herpes-simplex
virus-1 expressing five immunomodulatory transgenes, in subjects
with advanced injectable tumorsPresenter: Jong
Park, M.D., Instructor, Medicine, Harvard Medical School and
Assistant, Medicine, Massachusetts General HospitalAbstract
#: 511 Location: Poster Hall at the
Walter E. Washington Convention CenterDate and
Time: November 12–14th from 7:00 a.m.– 8:30 p.m. ET
An e-version of the poster will be available on Oncorus’
website, in the Publications & Presentations section, as of
7:00 a.m. ET on Friday, November 12th.
The submitted abstract reflects a data cut-off date of June 28,
2021, whereas the poster presentation will reflect a data cut-off
date of November 1, 2021. Additional data will be presented on
several evaluable patients treated with ONCR-177 monotherapy at the
recommended Phase 2 dose since the June cut-off date.
Conference Call and Webcast InformationOncorus
will host a conference call and live webcast with slides and
Q&A on Friday, November 12th at 8:30 a.m. ET. Igor Puzanov,
M.D., MSCI, FACP, who serves as Director of Center for Early Phase
Clinical Trials, Senior Vice President of Clinical Investigations,
and Chief of the Melanoma Section, at the Roswell Park
Comprehensive Cancer Center in Buffalo, New York, will join Oncorus
management for the call. Dr. Puzanov is also participating as an
investigator in the ONCR-177 Phase 1 clinical trial.
To participate in the conference call, please dial (833)
614-1530 (domestic) or (520) 809-9930 (international) and refer to
conference ID 8556488. A live webcast of the presentation will be
available at https://investors.oncorus.com/. A replay of the
webcast will be available shortly after the conclusion of the call
and archived on the Oncorus’ website for 30 days following the
call.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
oncolytic Herpes Simplex Virus (HSV) Platform and Synthetic viral
RNA (vRNA) Immunotherapy Platform.
Designed to deliver next-generation viral immunotherapy impact,
our HSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead HSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering Synthetic vRNA Immunotherapy Platform involves a highly
innovative, novel combination of RNA- and oncolytic virus-based
modalities designed to realize the potential of RNA medicines for
cancer. Our lead IV-administered Synthetic vRNA Immunotherapy
clinical candidates, ONCR-021 and ONCR-788, are both currently in
IND-enabling studies.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding the clinical development of ONCR-177,
including expectations regarding timing for reporting additional
data from the ongoing Phase 1 clinical trial of ONCR-177, as well
as the product candidate’s therapeutic potential and clinical
benefits and the utility and potential of Oncorus’ HSV Platform.
The words "may," “might,” "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," “expect,”
"estimate," “seek,” "predict," “future,” "project," "potential,"
"continue," "target" and similar words or expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks associated
with: the risk that the results of preclinical studies and early
results from clinical trials may not be predictive of future
clinical trial results; the impact of COVID-19 on Oncorus’
operations and the timing and anticipated results of its ongoing
and planned clinical trials; Oncorus’ ability to successfully
demonstrate the safety, tolerability and efficacy of ONCR-177,
ONCR-021 and ONCR-788, or any future product candidates, and obtain
regulatory approval thereof; Oncorus’ ability to obtain the
requisite components for its product candidates manufactured in
accordance with regulatory requirements; the expansion of Oncorus’
in-house manufacturing capabilities; the adequacy of Oncorus’ cash
resources and availability of financing on commercially reasonable
terms; and Oncorus’ ability to obtain, maintain and protect its
intellectual property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Oncorus’ Annual Report on Form 10-K for the year
ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10, 2021, as well as
discussions of potential risks, uncertainties, and other important
factors in the other filings that Oncorus makes with
the Securities and Exchange Commission from time to time.
These documents are available under the “SEC filings” page of the
Investors section of Oncorus’ website
at http://investors.oncorus.com. Any forward-looking
statements represent Oncorus’ views only as of the date of this
press release and should not be relied upon as representing its
views as of any subsequent date. Oncorus explicitly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Media Contact: Liz
Meloneliz@scientpr.com
Investor Contact: Stern Investor RelationsJulie
SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024